Allen Bui, MD
Vascular Surgery · Lafayette, LANPI 1285014688
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.6%), travel and lodging and grants — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Penumbra, Inc. at 34.8% of the total. Reporting peaked in 2022 at $7,573 and has fallen 60.8% since, to $2,966 in 2025.
Across 269 payments — averaging $69.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$7K
- Medtronic$4K
- Silk Road Medical, Inc.$2K
- W. L. Gore & Associates, Inc.$2K
- Cook Medical LLC$2K
- Boston Scientific$572
- plus $2K from 23 others
What the payments were for
- Grants$1,5838%
- Travel & lodging$6,91237%
- Food & beverage$10,19855%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 20 | $6,500 |
| Medtronic(2 entities) | 44 | $4,103 |
| Silk Road Medical, Inc. | 56 | $2,245 |
| W. L. Gore & Associates, Inc. | 19 | $1,921 |
| Cook Medical LLC | 34 | $1,823 |
| Boston Scientific | 36 | $572 |
| Shockwave Medical, Inc | 10 | $290 |
| Endologix LLC | 6 | $256 |
| Terumo Medical Corporation | 2 | $164 |
| Bard Peripheral Vascular, Inc. | 7 | $116 |
| Kerecis Limited | 4 | $92 |
| Inari Medical, Inc. | 2 | $77 |
| Johnson & Johnson | 3 | $53 |
| Argon Medical Devices, Inc. | 3 | $53 |
| Stryker | 2 | $48 |
| Smith+Nephew | 2 | $47 |
| Surmodics, Inc. | 3 | $43 |
| Artivion, Inc. | 2 | $39 |
| Sirtex Medical Inc | 2 | $36 |
| Truvic Medical, Inc. | 1 | $35 |
| Cvrx, Inc. | 1 | $34 |
| Abbott | 2 | $30 |
| BD | 1 | $24 |
| KCI USA, Inc. | 1 | $21 |
| Sanara Medtech Inc. | 2 | $19 |
| Humacyte Global, Inc. | 1 | $16 |
| Lemaitre Vascular, Inc. | 1 | $13 |
| Getinge USA Sales, LLC | 1 | $13 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$4,452
- ENROUTE Transcarotid Neuroprotection System$1,641
- RUBY Coil$1,511
- Endurant$1,411
- ENROUTE Transcarotid Stent$1,162
- ELLIPSYS VASCULAR ACCESS SYSTEM$1,131
- GORE TAG Thoracic Endoprosthesis$799
- VIABAHN VBX Balloon Expandable Endoprosthesis$372
- Cook Medical AFEN$330
- C3 Delivery System$271
- ENDURANT IIS$245
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$243
- ENROUTE Transcarotid Stent System$237
- ENHANCE Transcarotid Peripheral Access Kit$237
- ENROUTE 0.014 Guidewire$237
- Cook Medical Zenith$234
- Cook Medical Zilver PTX$228
- Valiant Navion$204
- Alto Abdominal Stent Graft System$150
- Azur CX Detachable$134
How this compares
$18,693 in reported general payments places this provider in the 80th percentile of 65 vascular surgery providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 54 | $32,272 |
| XareltoRivaroxaban | 48 | $31,655 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 151 | $1,126 |
| ClopidogrelClopidogrel Bisulfate | 129 | $895 |
| Gabapentin | 90 | $694 |
| Cilostazol | 38 | $404 |
| Atorvastatin Calcium | 38 | $203 |
| Pregabalin | 33 | $180 |
| Tizanidine Hcl | 25 | $170 |
| Cephalexin | 11 | $136 |
| Doxycycline Hyclate | 16 | $131 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $116 |
| Potassium Chloride | 16 | $65 |
| Tramadol Hcl | 11 | $46 |
| Furosemide | 33 | $45 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $53 | $31,65548 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 65 vascular surgery providers in Louisiana.
Other vascular surgery in Lafayette
- Christopher LagraizeLafayette$47K
- Joshua SibilleLafayette$17K
- John LukeLafayette$7K
- Angelle HoganLafayette$6K
- Racheed GhanamiLafayette$5K
- Michael Conners IiiBaton Rouge$70K
- Gregory CrenshawMetairie$67K
- James CravenBaton Rouge$65K
- Marvin WeaverBaton Rouge$58K
- Paul PerkowskiShreveport$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.